Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 5;133(9):1080-1086.
doi: 10.1097/CM9.0000000000000791.

Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial

Yuan-Yuan Qin  1 , Yi-Hong Zhou, Yan-Qiu Lu, Feng Sun, Sen Yang, Vijay Harypursat, Yao-Kai Chen
Affiliations

Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial

Yuan-Yuan Qin et al. Chin Med J (Engl). .

Abstract

Background: At the end of 2019, a novel coronavirus outbreak causative organism has been subsequently designated the 2019 novel coronavirus (2019-nCoV). The effectiveness of adjunctive glucocorticoid therapy in the management of 2019-nCoV-infected patients with severe lower respiratory tract infections is not clear, and warrants further investigation.

Methods: The present study will be conducted as an open-labeled, randomized, controlled trial. We will enrol 48 subjects from Chongqing Public Health Medical Center. Each eligible subject will be assigned to an intervention group (methylprednisolone via intravenous injection at a dose of 1-2 mg/kg/day for 3 days) or a control group (no glucocorticoid use) randomly, at a 1:1 ratio. Subjects in both groups will be invited for 28 days of follow-up which will be scheduled at four consecutive visit points. We will use the clinical improvement rate as our primary endpoint. Secondary endpoints include the timing of clinical improvement after intervention, duration of mechanical ventilation, duration of hospitalization, overall incidence of adverse events, as well as rate of adverse events at each visit, and mortality at 2 and 4 weeks.

Discussion: The present coronavirus outbreak is the third serious global coronavirus outbreak in the past two decades. Oral and parenteral glucocorticoids have been used in the management of severe respiratory symptoms in coronavirus-infected patients in the past. However, there remains no definitive evidence in the literature for or against the utilization of systemic glucocorticoids in seriously ill patients with coronavirus-related severe respiratory disease, or indeed in other types of severe respiratory disease. In this study, we hope to discover evidence either supporting or opposing the systemic therapeutic administration of glucocorticoids in patients with severe coronavirus disease 2019.

Trial registration: ClinicalTrials.gov, ChiCTR2000029386, http://www.chictr.org.cn/showproj.aspx?proj=48777.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Stratification flowchart of selection, randomization and follow-up of subjects with severe coronavirus disease 2019 (COVID-19) with or without glucocorticoid therapy.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020; 92:418–423. doi: 10.1002/jmv.25681. - PMC - PubMed
    1. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15:327–347. doi: 10.1038/nrd.2015.37. - PMC - PubMed
    1. WHO. Summary of probable SARS cases with onset of illness from November 1, 2002 to July 31, 2003. WHO, 2003. Available from: https://www.who.int/csr/sars/country/table2004_04_21/en/. [Accessed on February 2, 2020]
    1. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). 2019. Available from: http://www.who.int/emergencies/mers-cov/en/. [Accessed on February 2, 2020]
    1. WHO. Novel Coronavirus(2019-nCoV)SITUATION REPORT-121 JANUARY 2020. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... [Accessed January 20, 2020]

Publication types

Substances